Autologous induced pluripotent stem cell based therapy - Karis Bio
Alternative Names: Autologous iPSC-derived therapy - Karis BioLatest Information Update: 07 Oct 2025
At a glance
- Originator Karis Bio
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Coronary artery disease; Peripheral arterial disorders
Most Recent Events
- 15 Apr 2025 Preclinical trials in Coronary artery disease in South Korea (Parenteral) before April 2025
- 15 Apr 2025 Preclinical trials in Peripheral arterial disorders in South Korea (Parenteral) before April 2025
- 15 Apr 2025 Karis Bio plans a phase II trial for Coronary artery disease and Peripheral arterial disease